| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT06835569 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With… |
Enrollment increased: 188 -> 448 participants |
| 2026-06-11 | NCT06835569 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With… |
Trial arms changed: 2 -> 10 |
| 2026-06-10 | NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… |
Recruitment opened |
| 2026-06-09 | NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… |
Trial sites expanded: 192 -> 196 locations |
| 2026-06-06 | NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… |
Trial sites expanded: 241 -> 247 locations |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Primary completion moved earlier: 2029-02-02 -> 2028-04-23 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Completion moved earlier: 2030-08-06 -> 2029-10-25 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Primary completion pushed: 2026-04-03 -> 2027-12-31 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Completion pushed: 2029-07-27 -> 2030-07-03 |
| 2026-06-04 | NCT05308446 Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or… |
date change Primary completion moved earlier: 2026-09-30 -> 2026-02-28 |
| 2026-06-04 | NCT05308446 Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or… |
date change Completion pushed: 2026-09-30 -> 2027-06-01 |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Trial terminated — check why_stopped for reason |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
critical why stopped: null → "The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape." |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Enrollment reduced: 514 -> 47 participants |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Primary completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-06-03 | NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
Primary endpoint(s) modified |
| 2026-06-03 | NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
Enrollment increased: 387 -> 665 participants |
| 2026-06-03 | NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
Trial arms changed: 14 -> 20 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07621497 FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable… | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07618624 BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent… | Phase 2 | Enrolling by Invitation |
| 2026-05-19 | NCT07595276 Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07094893 | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type… | Colorectal Cancer | Not Yet Recruiting |
| Phase 3 | |||
| NCT07389265 | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | Metastatic Colorectal Cancer (mCRC) | Recruiting |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or… | Metastatic Head-and-neck Squamous-cell Carcinoma | Recruiting |
| NCT06706401 | Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma | Oropharynx Cancer | Recruiting |
| NCT04966481 | Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered… | HPV-unrelated Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of… | Metastatic Colorectal Carcinoma | Recruiting |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… | Colorectal Neoplasms | Recruiting |
| NCT04892173 | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Carcinoma, Squamous Cell | Recruiting |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… | Colorectal Neoplasms | Recruiting |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… | Colorectal Neoplasms | Recruiting |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… | Colon Adenocarcinoma | Recruiting |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment… | Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT00956007 | RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally… | Head and Neck Cancer | Active, Not Recruiting |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable… | Head and Neck Squamous Cell Carcinoma | Active, Not Recruiting |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC | Rectal Adenocarcinoma | Not Yet Recruiting |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced… | Advanced Colorectal Cancer | Active, Not Recruiting |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and… | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Not Yet Recruiting |
| NCT07595276 | Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally… | Colorectal Cancer | Not Yet Recruiting |
| NCT05239741 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage… | Colorectal Neoplasms | Active, Not Recruiting |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus… | Squamous Cell Carcinoma of the Head and Neck | Active, Not Recruiting |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With… | Neoplasms | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT01810913 | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to… | Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma | Recruiting |
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for… | Colon Adenocarcinoma | Active, Not Recruiting |
| NCT05063552 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without… | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Active, Not Recruiting |
| Phase 2 | |||
| NCT07063212 | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and… | Squamous Cell Carcinoma of Head and Neck | Recruiting |